摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-{4-[2-(2-{[amino(imino)methyl]amino}-1H-benzimidazol-6-yl)ethyl]thiazol-2-yl}acetamide | 878629-27-7

中文名称
——
中文别名
——
英文名称
N-{4-[2-(2-{[amino(imino)methyl]amino}-1H-benzimidazol-6-yl)ethyl]thiazol-2-yl}acetamide
英文别名
N-[4-[2-[2-(diaminomethylideneamino)-3H-benzimidazol-5-yl]ethyl]-1,3-thiazol-2-yl]acetamide
N-{4-[2-(2-{[amino(imino)methyl]amino}-1H-benzimidazol-6-yl)ethyl]thiazol-2-yl}acetamide化学式
CAS
878629-27-7
化学式
C15H17N7OS
mdl
——
分子量
343.412
InChiKey
KEVKADBDQBRUCP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.58±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    24
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    163
  • 氢给体数:
    4
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Thiazole Derivatives Having Vap-1 Inhibitory Activity
    申请人:Inoue Takayuki
    公开号:US20080015202A1
    公开(公告)日:2008-01-17
    A compound of the formula (I): U-V-W-X-Y-Z  (I) wherein U is lower alkyl; V is —CONH— or —NR 1 CO— wherein R 1 is a hydrogen or lower alkyl; W is a bond or lower alkylene; X is a bivalent residue derived from optionally substituted thiazole; Y is a bond or lower alkylene; and Z is a group of the formula: wherein R 2 is a group of the formula: -A-B-D-E-F-G wherein A is a bond or lower alkylene; B is a bond, —NH— or D is a bond, —CS— or —CO—; E is a bond or —NH—; F is a bond, —CO—, —O— or —SO 2 —; and G is lower alkyl, optionally protected amino, —OH, phenyl, R 3 is lower alkyl, provided that when Z is a group of the formula: then G should not be amino, when Z is a group of the formula: then G should not be when Z is a group of the formula: and G is optionally protected amino, then D should be —CS—, or then A should be lower alkylene, B or E should be —NH— and F should be —CO—; or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor as well as a pharmaceutical composition and a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.
    化合物的结构式(I):U-V-W-X-Y-Z  (I),其中U为低级烷基;V为—CONH—或—NR1CO—,其中R1为氢或低级烷基;W为键或低级亚烷基;X为源自可选取代噻唑的二价残基;Y为键或低级亚烷基;Z为下式的基团:其中R2为下式的基团:-A-B-D-E-F-G,其中A为键或低级亚烷基;B为键,—NH—或D为键,—CS—或—CO—;E为键或—NH—;F为键,—CO—,—O—或—SO2—;G为低级烷基,可选的保护氨基,—OH,苯基,R3为低级烷基,但当Z为下式的基团时:则G不应为氨基;当Z为下式的基团时:则G不应为;当Z为下式的基团时:若G为可选的保护氨基,则D应为—CS—,或者A应为低级亚烷基,B或E应为—NH—,F应为—CO—;或其药学上可接受的盐,作为血管黏附蛋白-1(VAP-1)抑制剂以及用于预防或治疗VAP-1相关疾病,特别是黄斑水肿的制剂组合物和方法,该方法包括向受体施用化合物或其药学上可接受的盐的有效量等。
  • THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY
    申请人:Astellas Pharma Inc.
    公开号:EP1791835A2
    公开(公告)日:2007-06-06
  • [EN] THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY<br/>[FR] DERIVES DU THIAZOLE PRESENTANT UNE ACTIVITE INHIBITRICE DE LA PROTEINE 1 D'ADHESION VASCULAIRE
    申请人:ASTELLAS PHARMA INC
    公开号:WO2006028269A2
    公开(公告)日:2006-03-16
    A compound of the formula (I): U-V-W-X-Y-Z (I) wherein U is lower alkyl; V is -CONH- or -NR1CO- wherein R1 is a hydrogen or lower alkyl; W is a bond or lower alkylene; X is a bivalent residue derived from optionally substituted thiazole; Y is a bond or lower alkylene; and Z is a group of the formula: (a) wherein R2 is a group of the formula: -A-B-D-E-F-G wherein A is a bond or lower alkylene; B is a bond, (b); D is a bond, -CS- or -CO-; E is a bond or -NH-; F is a bond, -CO-, -O- or -SO2-; and G is lower alkyl, optionally protected amino, -OH, phenyl, (c); and R3 is lower alkyl, provided that when Z is a group of the formula: (d), then G should not be amino, when Z is a group of the formula: (e), then G should not be (f), when Z is a group of the formula: (g) and G is optionally protected amino, then D should be -CS-, or then A should be lower alkylene, B or E should be -NH- and F should be -CO-; or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor as well as a pharmaceutical composition and a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.
  • [EN] THIAZOLE DERIVATIVES HAVING VAP-1 IHIBITORY ACTIVITY<br/>[FR] DERIVES DU THIAZOLE PRESENTANT UNE ACTIVITE INHIBITRICE DE LA PROTEINE 1 D'ADHESION VASCULAIRE
    申请人:ASTELLAS PHARMA INC
    公开号:WO2006028269A3
    公开(公告)日:2006-06-29
查看更多